Skip to main content
Log in

Comment on “Replicating Health Economic Models: Firm Foundations or a House of Cards?”

  • Letter to the Editor
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 27 September 2017

The Original Article was published on 26 July 2017

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. McManus E. How reproducible are economic decision-analytic models? A systematic review and replication study—study outline. 2016. Available at: http://www.clahrcprojects.co.uk/impact/publications/how-reproducible-are-economic-decision-analytic-models-systematic-review-and.

  2. Bermejo I, Tappenden P, Youn J. Replicating health economic models: firm foundations or a house of cards? Pharmacoeconomics. 2017. doi:10.1007/s40273-017-0553-x (Epub ahead of print).

    Google Scholar 

  3. McManus E, Sach T (2016) An assessment of the transparency and quality of decision-analytic models in an entire clinical area: a systematic review and replication study. Presented at The Health Economics Study Group Conference, Gran Canaria.

  4. The Reward Alliance, The REWARD statement. 2015. http://researchwaste.net/reward-statement/. Accessed 29 Aug 2017.

  5. Equator Network, EQUATOR Network: what we do and how we are organised. 2016. http://www.equator-network.org/about-us/. Accessed 29 Aug 2017.

  6. Tappenden P, Ren S, Archer R, Harvey R, Martyn St-James M, Basarir H, et al. A model-based economic evaluation of biologic and non-biologic options for the treatment of adults with moderately-to-severely active ulcerative colitis after the failure of conventional therapy. Pharmacoeconomics. 2016;34(10):1023–38.

    Article  PubMed  Google Scholar 

  7. Versteegh M. Impact on the incremental cost-effectiveness ratio of using alternatives to EQ-5D in a Markov model for multiple sclerosis. Pharmacoeconomics. 2016;34(11):1133–44.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm. 2007;13(3):245–61.

    PubMed  Google Scholar 

  9. Clemens MA. The meaning of failed replications: a review and proposal. J Econ Surv. 2017;31(1):326–42.

    Article  Google Scholar 

  10. Smolen L, Klein T, Kelton K. Replication of a published Markov chronic migraine cost-effectiveness analysis model for purposes of early phase adaptation and expansion. Value Health. 2015;83:A19.

    Article  Google Scholar 

  11. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D. Consolidated health economic evaluation reporting standards (CHEERS)—explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–50.

    Article  PubMed  Google Scholar 

  12. Philips Z, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004;8(36):1–158.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Emma McManus.

Ethics declarations

Funding source

This letter was written whilst Professor Tracey Sach was funded by a Career Development Fellowship (CDF-2014-07-006) supported by the National Institute for Health Research (NIHR). The views expressed in this paper are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.

Conflict of interest

The authors are working in the same research area, and are currently in receipt of funding to conduct a research project evaluating the reproducibility of decision-analytic models in health economics (CLAHRC East of England project HE7: Dec 2015).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McManus, E., Sach, T. Comment on “Replicating Health Economic Models: Firm Foundations or a House of Cards?”. PharmacoEconomics 35, 1187–1188 (2017). https://doi.org/10.1007/s40273-017-0576-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-017-0576-3

Navigation